Home/Pipeline/NG-303

NG-303

Plaque psoriasis

PreclinicalActive

Key Facts

Indication

Plaque psoriasis

Phase

Preclinical

Status

Active

Company

Nanogen Pharmaceutical Biotechnology

About Nanogen Pharmaceutical Biotechnology

South Korean biotech leveraging nanobody‑based therapeutics for oncology and immunology.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Plaque psoriasis Drugs

Drug	Company	Phase	Status
Piclidenoson (CF101)	Can Fite Biopharma	Phase III	Active
Psoriasis Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting
Encube-001	Encube Ethicals	Phase 1/2a	Active
ZL-1102 (CB001)	Crescendo Biologics	Phase 2	Active (Licensed to Zai Lab)
AX-158	Artax Biopharma	Phase 2	Active
Pepticom‑IL17	Pepticom	Lead Optimization	Active
JNJ-2113	Johnson & Johnson	Phase 3	Active
VTAMA® (tapinarof)	Roivant Sciences	Approved	Launched (Asset acquired by Organon, 2024)
Wynzora	Almirall	Marketed	Commercial Growth
JNJ-81201887 (via Janssen)	OmniAb	Approved	Approved in EU